Reports Q4 revenue $7.828M, consensus $7.07M. "We made substantial progress in 2022 as we work to develop our novel arenaviral immunotherapies against a variety of cancers and infectious diseases. Our lead candidate, HB-200, advanced to Phase 2 in combination with pembrolizumab for head and neck cancers; our HB-300 program in prostate cancer advanced toward the clinic with IND acceptance; and we added a strategic collaboration with Roche to develop our HB-700 program for KRAS-mutated cancers," said Joern Aldag, Chief Executive Officer at HOOKIPA. "We have started the year strongly with our HB-300 program now open for enrollment, and our HB-700 program achieving a key milestone as we move toward the clinic. We remain focused on driving our rich pipeline forward and generating clinical data that expands the evidence of our arenaviral platform technology to help address unmet needs in cancer."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HOOK:
- HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
- Hookipa Pharma appoints Terry Coelho to board of directors
- HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
- Hookipa Pharma achieves $10M milestone payment under Roche collaboration
- HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
